



# SIGACHI LABORATORIES LIMITED

Corporate Office: 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. (INDIA)  
Ph. : 040-23204230, 23204273 E-mail: sigachilaboratories@yahoo.co.in  
CIN: L24230TG1994PLC018786 GSTIN: 36AACCS8220M1Z4

Date: 31.07.2020

Head Listing & Compliance  
Metropolitan Stock Exchange of India Limited  
Vibgyor Towers, 4th Floor  
Plot No.62, G- Block, Opp Trident Hotel,  
Bandra Kurla Complex, Bandra (E)  
Mumbai - 400 098

Dear Sir,

Sub: outcome of the Board Meeting held today i.e., on 31<sup>st</sup> July, 2020 -- Reg.

Ref: Disclosure under Regulation 30 and 33 SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015- Reg.

\*\*\*

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e. Friday, 31<sup>st</sup> July, 2020 had inter-alia considered and approved the Audited Financial Results for the Quarter & Year ended 31<sup>st</sup> March, 2020. Accordingly, please find enclosed herewith the following

1. Statement of Audited Financial results for the quarter & year ended 31<sup>st</sup> March, 2020.
2. The Audit Report by M/s. Niranjana & Narayan, Chartered Accountants Hyderabad, Statutory Auditors of the Company on the financial results for the quarter and year ended 31<sup>st</sup> March, 2020.
3. Declaration in respect of Audit Report with unmodified opinion for the financial Year ended on 31<sup>st</sup> March, 2020.
4. Approval of Notice of 26<sup>th</sup> Annual General Meeting and the AGM will be held on Saturday, the 26<sup>th</sup> day of September, 2020 at 4.00 P.M. through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM').
5. The Register of Members and share transfer registers will be closed from Saturday, 19<sup>th</sup> September, 2020 to Saturday, 26<sup>th</sup> September, 2020 (both the days inclusive) and the record date (cut-off date) will be 18<sup>th</sup> September, 2020.
6. The Board recommended the reappointment of Sri. T. Adinarayana, as a director of the company, who retires by rotation, subject to the approval of shareholders in the ensuing Annual General Meeting.



# SIGACHI LABORATORIES LIMITED

Corporate Office: 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. (INDIA)  
Ph. : 040-23204230, 23204273 E-mail: sigachilaboratories@yahoo.co.in  
CIN: L24230TG1994PLC018786 GSTIN: 36AACCS8220M1Z4

7. Approved the reappointment of Sri. T. Govardhana Rao, as an independent Director of the company for the second term, whose current term expires on 28<sup>th</sup> September, 2020, for a further term of 5 years, with effect from 29<sup>th</sup> September, 2020, subject to the approval of the Shareholders by means of a Special Resolution.

8. Approval of Directors report of the company.

Kindly acknowledge the receipt of the same.

Thanking you,

Yours faithfully,  
For Sigachi Laboratories Limited

LEKHA SAI  
SURAPANE  
NI

Digitally signed by  
LEKHA SAI  
SURAPANENI  
Date: 2020.07.31  
18:46:43 +05'30'

(Lekha Sai Surapaneni)  
Company Secretary

The Meeting Commenced at 4.00 P.M.  
The Meeting Concluded at 6.30 P.M.

SIGACHI LABORATORIES LIMITED  
 Regd.Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.  
 Tel No.: 040 - 23204230 / 23204273,  
 Website:www.sillab.com, Email:sigachilaboratories@yahoo.co.in  
 CIN:L24230TG1994PLC018786

Statement of Audited Financial Results For The Quarter and Year Ended 31st March, 2020

(Rs. In Lakhs)

Sl.No	Particulars	Quarter ended			Year ended	
		31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
		Audited	Un Audited	Audited	Audited	Audited
1	Revenue From Operations	(45.05)	54.60	61.50	66.51	169.55
2	Other Income	12.49	25.77	10.24	106.07	28.23
3	Total Income (1+2)	(32.56)	80.37	71.74	172.58	197.78
4	Expenses					
	a) Cost of materials consumed	-	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-	-
	c) Change in Inventories	-	-	-	-	-
	d) Employee benefits expense	6.92	5.87	16.80	27.99	34.83
	e) Finance costs	-	-	-	-	-
	f) Depreciation and amortization expense	4.06	4.14	3.51	15.32	14.72
	g) Other expenses	3.46	2.23	11.12	12.64	20.83
	Total expenses	14.44	12.24	31.43	55.96	70.38
5	Profit/(loss) before exceptional and extraordinary items and tax (3-4)	(47.00)	68.13	40.31	116.62	127.40
6	Exceptional Items	-	-	-	-	-
7	Profit/(loss) before extraordinary items and tax (5-6)	(47.00)	68.13	40.31	116.62	127.40
8	Extraordinary items	-	-	-	-	-
9	Profit/(Loss) before tax (7-8)	(47.00)	68.13	40.31	116.62	127.40
10	Tax expense					
	(a) Current tax	20.02	12.00	10.86	44.03	26.61
	(b) Deferred tax	0.22	1.44	(4.73)	1.94	(3.72)
	Total Tax Expense	20.24	13.44	6.13	45.97	22.89
11	Profit/(Loss) for the Period (9-10)	(67.24)	54.69	34.18	70.65	104.51
12	Other Comprehensive Income (OCI)					
	(a) Items that will not be reclassified to profit or loss	(227.93)	26.94	47.14	(226.96)	45.01
	(b) Items that will be reclassified to profit or loss	-	-	-	-	-
	Total Other Comprehensive Income	(227.93)	26.94	47.14	(226.96)	45.01
	Total Comprehensive Income (11+12)	(295.17)	81.63	81.32	(156.31)	149.52
13	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	675.31	675.31	675.31	675.31	675.31
14	Other Equity	-	-	-	1,256.34	1,408.49
15	Earnings per equity share (of Rs.10/- each) (not annualized (Rs.))					
	(1) Basic	(1.00)	0.81	0.51	1.05	1.55
	(2) Diluted	(1.00)	0.81	0.51	1.05	1.55

Segment wise Revenue, Results and Capital Employed for the Quarter and Year Ended 31st March, 2020

(Rs.in Lakhs)

Sl.No	Particulars	Quarter ended			Year ended	
		31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
		Audited	Un Audited	Audited	Audited	Audited
1	Segment Revenue					
	a) Bulk Drugs and Intermediates (Lease Rents)	38.000	27.50	36.00	110.50	104.50
	b) Investments	(70.56)	52.87	35.74	62.08	93.28
	Total	(32.56)	80.37	71.74	172.58	197.78
	Less: Inter Segment Revenue	-	-	-	-	-
	Net sales/Income from Operations	(32.56)	80.37	71.74	172.58	197.78
2	Segment Results Profit/ (Loss) before tax and finance Costs from each segment					
	a) Bulk Drugs and Intermediates (Lease Rents)	33.39	23.21	31.91	93.55	88.10
	b) Investments	(70.56)	52.87	35.74	62.07	93.28
	Total	(37.17)	76.08	67.65	155.62	181.38
	Less: (i) Finance Costs	-	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	9.83	7.95	27.34	39.00	53.98
	(iii) Un-allocable income	-	-	-	-	-
	Total Profit Before Tax	(47.00)	68.13	40.31	116.62	127.40
3	Capital Employed					
	(Segment assets – Segment Liabilities)					
	a) Bulk Drugs and Intermediates	576.05	568.68	490.28	576.05	490.28
	b) Investments	1,411.34	1,713.88	1,649.26	1,411.34	1,649.26
	Total	1,987.39	2,282.56	2,139.54	1,987.39	2,139.54

Notes :

- The above Financial results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their respective Meetings held on 31st July, 2020. These financial results are also available on the website of Metropolitan Stock Exchange of India Limited (www.msei.in) and also on the website of the Company (www.slilab.com).
- The Covid-19 continues to spread across the globe and India, which has contributed to a significant decline and volatility in global and Indian Financial Markets and a decrease in the economic activities. Given the virulent nature of the pandemic situation, the carrying value of the company's Investments as at 31st March, 2020, have been effected by the severity and duration of the outbreak; however the Company believes that it has taken into account all the possible impact of known events arising out of Covid-19 pandemic in the preparation of financial results resulting out of fair valuation of these investments. However, the impact assessment of Covid-19 is a continuing process given its nature and duration. The Company will continue to monitor for any material changes in this regard.
- The figures for the quarter ended 31st March, 2020 and 31st March, 2019 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter of the respective financial year which were subjected to limited review.
- Previous year / period figures have been recasted / regrouped / reclassified wherever necessary to make them comparable with current year / period figures.

By Order of the Board  
for SIGACHI LABORATORIES LIMITED

T  
RAJASEKHAR  
Digitally signed by  
T RAJASEKHAR  
Date: 2020.07.31  
18:51:01 +05'30'

(T.R.Sekhar)

Executive Director

DIN:02943146

Place : Hyderabad

Date : 31.07.2020

**SIGACHI LABORATORIES LIMITED**  
 Regd. Office: S.No: 530 & 534, Bonthapally - 502 313.  
 Gummadidala Mandal, Sanga Reddy District, Telangana.  
 Tel No.: 040 - 23204230 / 23204273,  
 Website: www.slllab.com, Email: sigachilaboratories@yahoo.co.in  
 CIN: L24230TG1994PLC018786

Statement of Assets and Liabilities as at 31st March, 2020.

(Rs. in Lakhs)

Particulars	As at 31.03.2020	As at 31.03.2019
<b>A. ASSETS</b>		
1. Non-Current Assets		
(a) Property Plant and Equipment	261.65	271.49
(b) Financial Assets		
(i) Investments	1,239.05	1,584.27
(ii) Other Financial Assets	43.53	43.53
(c) Other non Current Assets	-	26.12
<b>Total Non - Current Assets</b>	<b>1,544.23</b>	<b>1,925.41</b>
2. Current Assets		
(a) Financial Assets		
(i) Investments	21.26	20.42
(ii) Trade Receivables	20.85	14.68
(iii) Cash and Cash Equivalents	210.17	202.88
(iv) Other Financial Assets	172.29	65.00
(b) Other Current Assets	76.05	-
<b>Total Current Assets</b>	<b>500.62</b>	<b>302.98</b>
<b>Total Assets</b>	<b>2,044.85</b>	<b>2,228.39</b>
<b>B. EQUITY AND LIABILITIES</b>		
1. Equity		
(a) Equity Share Capital	731.06	731.06
(b) Other Equity	1,256.34	1,408.49
<b>Total Equity</b>	<b>1,987.40</b>	<b>2,139.55</b>
2. Liabilities		
Non-Current Liabilities		
(a) Financial Liabilities	-	-
(b) Long term Provisions	1.96	1.02
(c) Deferred Tax Liabilities (net)	19.31	8.52
(d) Other non - Current Liabilities	25.00	25.00
<b>Total Non - Current Liabilities</b>	<b>46.27</b>	<b>34.54</b>
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payables	-	-
(iii) Other Financial Liabilities	11.18	54.30
(b) Provisions	-	-
(c) Other Current Liabilities	-	-
<b>Total Current Liabilities</b>	<b>11.18</b>	<b>54.30</b>
<b>Total Equity and Liabilities</b>	<b>2,044.85</b>	<b>2,228.39</b>

By Order of the Board  
for SIGACHI LABORATORIES LIMITED

T  
RAJASEKHAR  
Digitally signed by T  
RAJASEKHAR  
Date: 2020.07.31 18:46:12  
+05'30'

(T.R.Sekhar)

Executive Director

DIN:02943146

Place : Hyderabad

Date : 31.07.2020

<b>Sigachi Laboratories Limited</b>		
<b>CASH FLOW STATEMENT FOR THE YEAR ENDED 31.03.2020</b>		
(Rs. in Lakhs)		
Particulars	Year Ended 31.03.2020 Rs.	Year ended 31.03.2019 Rs.
<b>Cash Flows from Operating Activities</b>		
Net profit before tax	116.62	127.40
Adjustments for :		
Depreciation and amortization expense	15.32	14.72
Profit / Loss on Sale of Investments	-	(0.39)
Dividend Received	(26.95)	(19.90)
Provision for Gratuity & Leave Encashment	0.95	-
Profit on Margadarshi Chit	(3.34)	-
Bad Debts/Deposits Recovery	(0.61)	-
Profit on sale of assets	(63.16)	-
Interest	(65.72)	(70.27)
Fair Value Gains/Losses	97.70	(2.72)
Operating profit before working capital changes	<b>70.81</b>	48.84
Movements in Working Capital		
(Increase)/Decrease in Trade Receivables	(6.17)	(5.50)
(Increase)/Decrease in Other financial assets	(107.29)	5.50
(Increase)/Decrease in Other Current Assets	(76.05)	0.34
(Increase)/Decrease in Other Non Current Assets	26.12	(6.92)
Increase/(Decrease) in Other financial liabilities	(38.96)	48.99
Increase/(Decrease) in Other Non Current Liabilities	-	(11.76)
Changes in Working Capital	<b>(202.35)</b>	30.65
<b>Cash generated from operations</b>	<b>(131.55)</b>	79.49
Direct Taxes Paid	35.17	26.61
<b>Net Cash from operating activities (A)</b>	<b>(166.72)</b>	52.88
<b>Cash flows from Investing Activities</b>		
Purchase of Fixed Assets	(21.53)	(10.28)
Sale of Fixed Assets	16.05	-
Purchase/Sale of Investments (Net Aggregate)	(123.49)	20.31
Fire Insurance Claim Received	-	30.21
Dividend Received	26.95	19.90
Profit on Margadarshi Chit	3.34	-
Bad Debts/Deposits Recovery	0.61	-
Profit on sale of assets	63.16	-
Interest	65.72	70.27
(Increase) /Decrease in other term deposits	143.20	-
<b>Net Cash used in Investing Activities (B)</b>	<b>174.01</b>	130.41
<b>Cash flows from/(used in) Financing Activities</b>		
Proceeds from Long term borrowings		
Repayment/(Proceeds) of/from Short-term borrowings		
Dividend paid		
Corporate Dividend tax		
<b>Net Cash used in Financing Activities (C)</b>	-	-
<b>Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)</b>	<b>7.29</b>	183.28
Cash and Cash Equivalents at the beginning of the year	202.88	19.60
Cash and Cash Equivalents at the ending of the year	<b>210.17</b>	202.88

By Order of the Board  
for Sigachi Laboratories Limited

T  
RAJASEKH  
AR

Digitally signed  
by T RAJASEKHAR  
Date: 2020.07.31  
18:51:44 +05'30'

(T.R.Sekhar)  
Executive Director  
DIN:02943146

Place : Hyderabad  
Date : 31.07.2020



# niranjan & narayan

## Chartered Accountants

FRN : 005899S

GSTIN : 36AACFN0604K1ZJ

first floor, h.no: 7-1-28/1/A/21

shyamkaran road, ameerpet

hyderabad - 500 016

tel : 29806074, cell : 9490189487

email : caniranjan@yahoo.com

www.nncas.com

### INDEPENDENT AUDITOR'S REPORT

#### TO THE BOARD OF DIRECTORS OF SIGACHI LABORATORIES LIMITED

#### Report on the audit of the Standalone Financial Results

#### Opinion

We have audited the accompanying standalone quarterly financial results of **SIGACHI LABORATORIES LIMITED** (the company) for the quarter ended 31<sup>st</sup> March, 2020 and the year to date results for the period from 1<sup>st</sup> April, 2019 to 31<sup>st</sup> March, 2020, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the quarter ended 31<sup>st</sup> March, 2020 as well as the year to date results for the period from 1<sup>st</sup> April, 2020 to 31<sup>st</sup> March, 2020.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.





### **Emphasis of Matter Paragraph**

We draw attention to Note no: 2 of the financial results of the company wherein the financial impact of the Covid 19 on the operations of the company has been disclosed. Further the extent to which the Covid 19 pandemic will impact the Company's financial performance is dependent on the future developments which are highly uncertain. Our opinion is not modified in this matter.

### **Management's Responsibilities for the Standalone Financial Results**

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

*M. Mohan*





As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
  - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
  - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
  - Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
  - Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Place: Hyderabad  
Date: 31.07.2020

For Niranjana & Narayan  
Chartered Accountants  
FRN:005899S



M. Niranja

Partner- Memb No. 029552

UDIN: 20029552AAAAHT2619



# SIGACHI LABORATORIES LIMITED

Corporate Office: 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. (INDIA)  
Ph. : 040-23204230, 23204273 E-mail: sigachilaboratories@yahoo.co.in  
CIN: L24230TG1994PLC018786 GSTIN: 36AACCS8220M1Z4

Date: 31.07.2020

Head Listing & Compliance,  
Metropolitan Stock Exchange of India Limited,  
Vibgyor Towers, 4<sup>th</sup> Floor,  
Plot No.62, G-Block, Opp Trident Hotel,  
Bandra Kurla complex, Bandra (E),  
Mumbai – 400 098

Scrip Code:

Dear Sirs,

Re: Declaration relating to the Unmodified Opinion by Statutory Auditors on the Audited Financial Statements for the Fourth Quarter and Year ended 31<sup>st</sup> March, 2020, in accordance with Regulation 33(3)(D) of the SEBI (LODR) Regulations, 2015.

\*\*\*

We hereby declare that the Statutory Auditors of the Company have given their Unmodified Opinion on the Audited Financial Statements of the Company for the Fourth Quarter and Year ended 31<sup>st</sup> March, 2020.

Please take the above declaration on record.

Thanking you,

Yours faithfully  
For Sigachi Laboratories Limited,

T  
RAJASEK  
HAR

Digitally signed  
by T  
RAJASEKHAR  
Date: 2020.07.31  
18:47:27 +05'30'

Executive Director